Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19861681 | 1.00 | RORC (0.35) | RORCKDM4CNPC1RAB9A | |
| SCHEMBL15742232 | 1.00 | RORC (0.35) | RORCKDM4CNPC1RAB9A | |
| SCHEMBL17438427 | 1.00 | RORC (0.35) | RORCKDM4CNPC1RAB9A | |
| SCHEMBL17438429 | 1.00 | RORC (0.35) | RORCKDM4CNPC1RAB9A | |
| SCHEMBL15742228 | 1.00 | RORC (0.35) | RORCKDM4CNPC1RAB9A | |
| SCHEMBL15742230 | 1.00 | RORC (0.35) | RORCKDM4CNPC1RAB9A | |
| SCHEMBL17438596 | 0.90 | KDM4C (0.31) | KDM4CNPC1RAB9A | |
| SCHEMBL17438293 | 0.90 | KDM4C (0.31) | KDM4CNPC1RAB9A | |
| SCHEMBL15742243 | 0.90 | KDM4C (0.31) | KDM4CNPC1RAB9A | |
| SCHEMBL15749126 | 0.90 | KDM4C (0.31) | KDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016948-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | RORC 3750/4885KDM4C 3276/4885NPC1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.